Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study

被引：0

作者：

Smit, E. ^{[1
]}

Ahn, M-J ^{[2
]}

Dagogo-Jack, I. ^{[3
]}

Felip, E. ^{[4
]}

Gelsomino, F. ^{[5
]}

Johnson, B. ^{[6
]}

Johnson, M. ^{[7
]}

Negrao, M. V. ^{[8
]}

Offin, M. ^{[9
]}

Ramalingam, S. ^{[10
]}

Sanborn, R. ^{[11
]}

Tsao, A. ^{[8
]}

Wilner, K. ^{[12
]}

Alcasid, A. ^{[13
]}

Usari, T. ^{[14
]}

Zhang, X. ^{[15
]}

Riely, G. ^{[9
]}

机构：

[1] Leiden Univ, Med Ctr, Leiden, Netherlands

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[5] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[11] Providence Canc Inst, Earle A Chiles Res Inst, Providence, RI USA

[12] Pfizer, La Jolla, CA USA

[13] Pfizer, Collegeville, PA USA

[14] Pfizer, Milan, Italy

[15] Pfizer, San Francisco, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

non-small cell lung cancer; encorafenib; binimetinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA06.13

引用

页码：S77 / S78

页数：2

共 35 条

[31] Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Zimmer, Lisa
Livingstone, Elisabeth
Krackhardt, Angela
Schultz, Erwin S.
Goppner, Daniela
Assaf, Chalid
Trebing, Dietrich
Stelter, Kai
Windemuth-Kieselbach, Christine
Ugurel, Selma
Schadendorf, Dirk
EUROPEAN JOURNAL OF CANCER, 2021, 158 : 72 - 84
[32] Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series
Ji, Jingran
Wang, Chongkai
Fakih, Marwan
CLINICAL COLORECTAL CANCER, 2022, 21 (03) : 267 - 271
[33] VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study
Chen, Yijiao
Zhu, Dexiang
Yu, Yiyi
Chang, Wenju
Ye, Lechi
Feng, Qingyang
Xu, Pingping
Chen, Miao
Ji, Meiling
Wei, Ye
Liu, Tianshu
Xu, Jianmin
CLINICAL COLORECTAL CANCER, 2024, 23 (04) : 354 - 363.e4
[34] Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study
Shi, Yuankai
Han, Xiaohong
Zhao, Qian
Zheng, Yulong
Chen, Jianhua
Yu, Xinmin
Fang, Jian
Liu, Yutao
Huang, Dingzhi
Liu, Tianshu
Shen, Hong
Luo, Suxia
Yu, Hongsheng
Cao, Yu
Zhang, Xi
Hu, Pei
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
[35] Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Swalduz, Aurelie
Beau-Faller, Michele
Planchard, David
Mazieres, Julien
Bayle-Bleuez, Sophie
Debieuvre, Didier
Fallet, Vincent
Geier, Margaux
Cortot, Alexis
Couraud, Sebastien
Daniel, Catherine
Domblides, Charlotte
Pichon, Eric
Fabre, Elizabeth
Larive, Sebastien
Lerolle, Ulrike
Tomasini, Pascale
Wislez, Marie
Missy, Pascale
Morin, Franck
Westeel, Virginie
Auliac, Jean-Bernard
LUNG CANCER, 2025, 199

← 1 2 3 4 →